New Oral Weight Loss Pill Mimicking GLP-1 Hormone Arrives in Israel

A new daily oral tablet that mimics the effects of the GLP-1 hormone, previously only available via injection, is now accessible in Israel for treating obesity and overweight conditions. This novel medication, approved in the U.S. in April 2026, offers a convenient alternative for individuals who prefer not to use injections or find them difficult to manage. The pill works by increasing feelings of fullness, reducing hunger, and curbing cravings, thereby decreasing food intake and influencing appetite centers in the brain. It also aids in blood sugar regulation by increasing insulin secretion and decreasing glucagon secretion when blood sugar is high, and slows gastric emptying.

Clinical trials, such as the ATTAIN-1 study involving over 3,000 adults, demonstrated significant weight loss, with the highest dosage leading to an average reduction of 11.1% of body weight over 72 weeks. Approximately 72% of participants in the high-dose group lost at least 5% of their body weight, with 18% achieving a 20% or greater reduction. While effective, individual responses vary, and the drug is intended as part of a comprehensive treatment plan including diet and exercise, not as a standalone solution.

The medication is prescribed for adults with a BMI of 30 or higher, or 27 or higher with weight-related comorbidities like hypertension, dyslipidemia, sleep apnea, cardiovascular disease, or type 2 diabetes. Treatment begins at a low dose and gradually increases to minimize gastrointestinal side effects such as nausea, diarrhea, and constipation, which are common but often subside over time. Patients are advised to consult their doctor regarding potential interactions with other medications and specific contraindications, including a history of certain thyroid cancers or pancreatitis.

While the oral tablet offers a new option, its efficacy compared to injectable GLP-1 medications is not definitively established, as direct comparative studies are lacking. The choice of treatment depends on individual medical conditions, preferences, and treatment goals. Experts emphasize that obesity is a chronic condition, and long-term management, including maintaining results and addressing potential weight regain after discontinuing treatment, is crucial for sustained health benefits.